EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Piperacillin–tazobactam tolerability in patients with a labeled penicillin allergy (PIPPEN)

Avneet Purewal, Kieran Shah, Sarah N. Stabler, Kevin Afra, Ke Su

Antimicrobial Stewardship & Healthcare Epidemiology · 2026 · 6 (1)

DOI: 10.1017/ash.2026.10322 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background: Piperacillin–tazobactam is a beta-lactam antibiotic with a distinct R1 side chain compared to other penicillins, therefore the risk of cross-reactivity should be theoretically low. Despite this difference, antimicrobial guidelines recommend against using piperacillin–tazobactam in patients with penicillin allergies. There is limited data available regarding piperacillin–tazobactam use in patients with a penicillin allergy, or rates of cross-reactivity. Therefore, the objective of this study was to assess the incidence of cross-reactivity to piperacillin–tazobactam in patients with a labeled penicillin allergy. Methods: This was a retrospective study of patients admitted to Surrey Memorial Hospital (SMH) between November 1 st , 2021 to January 31 st , 2024 assessing tolerance to piperacillin–tazobactam in patients with prior labeled penicillin allergies. Baseline characteristics and outcomes were collected from electronic medical records (EMR). Results: Of the 191 patients included, 98% were found to tolerate one or more doses of piperacillin–tazobactam. This included 95 patients with “low risk delayed reactions,” 90 patients with “high risk anaphylactic reactions,” and 2 patients with “well-documented delayed reactions,” to penicillins. Only four patients out of 191 had documented intolerance to piperacillin-tazobactam post-exposure. Conclusion: This study suggests that piperacillin–tazobactam has a low risk of intolerability (2%) in patients with labeled penicillin allergies, and that it is reasonable to consider piperacillin–tazobactam as an alternative to carbapenems and other broad-spectrum antibiotics for most patients with a previous penicillin allergy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →